type here...
type here...
START FREE TRIAL

Healthcare

Technology & AIM&AHealthcareConsumer & RetailMedia & EntertainmentIndustrials

BioMarin Amicus Acquisition: A $4.8 Billion Bet on Rare Disease Domination

Healthcare Ishan Majumdar -
BioMarin Pharmaceutical (NASDAQ:BMRN) just made its boldest move in years—unveiling a $4.8 billion all-cash acquisition of Amicus Therapeutics. The move, announced in December 2025,...

Eli Lilly Adverum Acquisition Could Reshape Gene Therapy!

Healthcare Ishan Majumdar -
Eli Lilly (NYSE:LLY) isn’t slowing down. After a quarter filled with blockbuster drug launches, accelerated global uptake of Mounjaro and Zepbound, and $12 billion...
spot_imgspot_img

Mirum Bluejay Acquisition Unlocks Rare Disease Gold!

Healthcare Ishan M. -
Mirum Pharmaceuticals (NASDAQ:MIRM) is making big moves. In early December 2025, the company announced its plan to acquire privately...

Novartis Gene Therapy Approval: A New Multi-Billion Dollar Market?

Healthcare Ishan M. -
Novartis just scored a big win with a major Novartis gene therapy approval —and it could reshape the gene...

Johnson & Johnson Halda Acquisition: The $3.05 Billion Gamble!

Healthcare Ishan Majumdar -
Johnson & Johnson just made another big move. The company announced that it will buy Halda Therapeutics for $3.05...

Merck Cidara Acquisition: $9.2B Flu Drug Deal to Replace Keytruda

Healthcare Ishan Majumdar -
Merck isn’t waiting around for Keytruda’s patent clock to run out. On November 14, the pharma giant announced its...

Cogent Biosciences’ Cancer Drug Exploded to 136% —Can the Rally Actually Last?

Healthcare Ishan Majumdar -
It’s not every day you see a biotech stock jump 136% before lunch. But that’s exactly what happened with...

Premier Inc. Draws Buyout Interest From Patient Square Capital — Here’s Why This Deal Could Happen

Healthcare Ishan Majumdar -
Premier Inc, a healthcare group purchasing and technology company, has recently become the subject of acquisition interest from private...
Load more

BioMarin Amicus Acquisition: A $4.8 Billion Bet on Rare Disease Domination

Healthcare Ishan Majumdar -
BioMarin Pharmaceutical (NASDAQ:BMRN) just made its boldest move in years—unveiling a $4.8 billion all-cash acquisition of Amicus Therapeutics. The...

Eli Lilly Adverum Acquisition Could Reshape Gene Therapy!

Healthcare Ishan Majumdar -
Eli Lilly (NYSE:LLY) isn’t slowing down. After a quarter filled with blockbuster drug launches, accelerated global uptake of Mounjaro...

Mirum Bluejay Acquisition Unlocks Rare Disease Gold!

Healthcare Ishan M. -
Mirum Pharmaceuticals (NASDAQ:MIRM) is making big moves. In early December 2025, the company announced its plan to acquire privately...

Novartis Gene Therapy Approval: A New Multi-Billion Dollar Market?

Healthcare Ishan M. -
Novartis just scored a big win with a major Novartis gene therapy approval —and it could reshape the gene...

Johnson & Johnson Halda Acquisition: The $3.05 Billion Gamble!

Healthcare Ishan Majumdar -
Johnson & Johnson just made another big move. The company announced that it will buy Halda Therapeutics for $3.05...

Merck Cidara Acquisition: $9.2B Flu Drug Deal to Replace Keytruda

Healthcare Ishan Majumdar -
Merck isn’t waiting around for Keytruda’s patent clock to run out. On November 14, the pharma giant announced its...

Cogent Biosciences’ Cancer Drug Exploded to 136% —Can the Rally Actually Last?

Healthcare Ishan Majumdar -
It’s not every day you see a biotech stock jump 136% before lunch. But that’s exactly what happened with...

Premier Inc. Draws Buyout Interest From Patient Square Capital — Here’s Why This Deal Could Happen

Healthcare Ishan Majumdar -
Premier Inc, a healthcare group purchasing and technology company, has recently become the subject of acquisition interest from private...

GE Healthcare’s Neurology Bet: Can The Icometrix Acquisition Unlock The Alzheimer’s Diagnosis Market?

Healthcare Ishan Majumdar -
GE HealthCare has deepened its push into precision medicine with a strategic agreement to acquire icometrix, a Belgium-based firm...

Jamf Holding’s $1.4 Billion Shakeup: Citigroup Tapped As Vista Plots Its Exit

Healthcare Ishan Majumdar -
Jamf Holding Corp., a leading Apple-focused device management and security software provider, has become the subject of renewed M&A...

Kenvue Crashing?—New RFK Jr. Report May Blame Tylenol Use In Pregnancy For Autism

Healthcare Ishan Majumdar -
Shares of Kenvue Inc., maker of Tylenol, dropped roughly 10% in early September 2025 after media reports—primarily from The...

Alcon’s Purchase Of STAAR Signals A New Chapter In Surgical Eye Care

Healthcare Ishan Majumdar -
Alcon’s recent agreement to acquire STAAR Surgical for $28 per share—representing a 59% premium to STAAR’s 90-day VWAP and...
Load more

Baptista Research is a financial research house focused on the U.S. markets. We cover the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms.

Company

Headlines

BioMarin Amicus Acquisition: A $4.8 Billion Bet on Rare Disease Domination

0
BioMarin Pharmaceutical (NASDAQ:BMRN) just made its boldest move in...

Meta Mango Image Video AI Is Coming for Google’s Nano Banana & Adobe!!

0
Meta Platforms (NASDAQ:META) is getting serious about becoming a...

Blue Owl Exit Puts Oracle AI Data Center Funding Strategy in Question

0
Oracle's (NYSE:ORCL) AI ambitions may have been too big,...

How To Read A Stock Research Report: Valuation, Risks & Key Metrics Explained

0
If you have ever opened a professional stock research...

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2025 Baptista Research. All rights reserved.